GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovaro Inc (FRA:2Q5) » Definitions » Institutional Ownership

Renovaro (FRA:2Q5) Institutional Ownership : 5.43% (As of Jun. 04, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Renovaro Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Renovaro's institutional ownership is 5.43%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Renovaro's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Renovaro's Float Percentage Of Total Shares Outstanding is 64.62%.


Renovaro Institutional Ownership Historical Data

The historical data trend for Renovaro's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renovaro Institutional Ownership Chart

Renovaro Historical Data

The historical data trend for Renovaro can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 0.61 0.61 1.08 1.09 1.11 1.21 1.23 0.59 5.44 5.43

Renovaro Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Renovaro (FRA:2Q5) Business Description

Traded in Other Exchanges
Address
2080 Century Park East, Suite 906, Los Angeles, CA, USA, 90067
Renovaro Biosciences Inc Formerly Enochian BioSciences Inc is a biopharmaceutical company. It is engaged in the research and development of pharmaceutical and biological products for the treatment of HIV, HBV, and cancer with the intent to manufacture said products.

Renovaro (FRA:2Q5) Headlines

No Headlines